With eye on winning over FDA in the wake of RTF, Zogenix publishes new Fintepla data
Battered by a refuse-to-file letter from the FDA in April, Zogenix has made strides to convince the FDA that its Dravet syndrome drug is worth …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
